Loading
A phase 2 trial of Sunvozertinib and Bevacizumab in non-small-cell lung cancer, run by Dizal Pharmaceuticals, now recruiting.
DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29) is a phase 2 interventional study registered as NCT06276283 by Dizal Pharmaceuticals, with 60 participants planned, started 2023-02-15 and due to reach its primary completion in 2025-12-31. Interventions recorded: DZD9008 plus Bevacizumab.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares Dizal Pharmaceutical, Small-molecule kinase inhibitors and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.